

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM678301

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
U.S. Bank National Association		09/30/2021	National Banking Association: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Pharmaceutical Strategies Group, LLC		
<b>Street Address:</b>	5360 Legacy Drive, Bldg. 3, Suite 230		
<b>City:</b>	Plano		
<b>State/Country:</b>	TEXAS		
<b>Postal Code:</b>	75024		
<b>Entity Type:</b>	Limited Liability Company: TEXAS		
<b>Name:</b>	Artemetrx, LLC		
<b>Street Address:</b>	7101 Executive Center Drive, Suite 5-145		
<b>City:</b>	Brentwood		
<b>State/Country:</b>	TENNESSEE		
<b>Postal Code:</b>	37027		
<b>Entity Type:</b>	Limited Liability Company: TEXAS		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4242118	PHARMACEUTICAL STRATEGIES GROUP	
<b>Registration Number:</b>	4312545	PSG	
<b>Registration Number:</b>	4703032	ARTEMETRX	
<b>Registration Number:</b>	5687875	SPECIALTY DIAGNOSTIC	
<b>Registration Number:</b>	5687874	SPECIALTY MONITOR	
<b>Registration Number:</b>	6096773	COGNETA	
<b>Registration Number:</b>	5458399	RXWIRE	
<b>Registration Number:</b>	5458398	RXDIAGNOSTIC	
<b>Registration Number:</b>	4640168	A LEGACY OF SERVICE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6172359493		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent</i>			

CH \$240.00 4242118

*using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 6179517790  
**Email:** ronald.duvernay@ropesgray.com  
**Correspondent Name:** Ronald M. Duvernay  
**Address Line 1:** Prudential Tower, 800 Boylston Street  
**Address Line 2:** Ropes & Gray LLP  
**Address Line 4:** Boston, MASSACHUSETTS 02199-3600

<b>ATTORNEY DOCKET NUMBER:</b>	115096-0016-006
--------------------------------	-----------------

<b>NAME OF SUBMITTER:</b>	Ronald M. Duvernay
---------------------------	--------------------

<b>SIGNATURE:</b>	/r duvernay/
-------------------	--------------

<b>DATE SIGNED:</b>	09/30/2021
---------------------	------------

**Total Attachments: 3**

source=Release 4#page1.tif

source=Release 4#page2.tif

source=Release 4#page3.tif

**First Lien Release of Security Interest in Trademarks**

This First Lien Release of Security Interest in Trademarks, dated as of **September 30, 2021** (the “Release”), is made by **U.S. BANK NATIONAL ASSOCIATION**, as collateral agent (in such capacity, the “Agent”) in favor of **PHARMACEUTICAL STRATEGIES GROUP, LLC** and **ARTEMETRX, LLC** (both a “Grantor” and collectively the “Grantors”).

WHEREAS, by (i) that certain First Lien Security Agreement, dated as of **April 30, 2020** in favor of Agent (as amended, restated, or modified from time to time, the “Security Agreement”) and (ii) that certain related First Lien Trademark Security Agreement, dated as of **April 30, 2021** in favor of Agent (as amended, restated, or modified from time to time, the “Trademark Security Agreement”; capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Security Agreement or Trademark Security Agreement, as applicable), the Grantors granted to Agent, for the benefit of the Secured Parties, a lien on and security interest in all of the Grantors’ right, title and interest in, to and under the Collateral (as defined in the Trademark Security Agreement), including those Trademarks listed on Schedule I hereto;

WHEREAS, the Grantors desire Agent to release, discharge, terminate and cancel its lien on and security interest in the Collateral of the Grantors (as defined in the Trademark Security Agreement), including, without limitation, the Trademarks set forth on Schedule I hereto;


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Agent, on behalf of the Secured Parties, does hereby release, discharge, terminate and cancel any and all of its right, title and interest in and to the Collateral of the Grantors (as defined in the Trademark Security Agreement), including any and all goodwill relating to the same, and assigns, transfers and conveys to Grantors any and all of its rights, title and interests in the Collateral.

The Agent authorizes and requests that the Commissioner for Trademarks and any other applicable government officer record this Release.

This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature page follows]

**U.S. BANK NATIONAL ASSOCIATION  
AS COLLATERAL AGENT,**

By:   
Name: Benjamin J. Krueger  
Title: Vice President

**Schedule 1**

TRADEMARKS

<b>Registered Owner</b>	<b>Post-Closing Owner (if changing)</b>	<b>Registration No.</b>	<b>Trademark</b>
Pharmaceutical Strategies Group, LLC	N/A	4242118	PHARMACEUTICAL STRATEGIES GROUP
Pharmaceutical Strategies Group, LLC	N/A	4312545	PSG (LOGO DESIGN PLUS LETTERS "PSG") 
Artemetrx, LLC	N/A	4703032	ARTEMETRX
Artemetrx, LLC	N/A	5687875	SPECIALTY DIAGNOSTIC
Artemetrx, LLC	N/A	5687874	SPECIALTY MONITOR
Pharmaceutical Strategies Group, LLC	N/A	6096773	COGNETA
Pharmaceutical Strategies Group, LLC	N/A	5458399	RXWIRE
Pharmaceutical Strategies Group, LLC	N/A	5458398	RXDIAGNOSTIC
Pharmaceutical Strategies Group, LLC	N/A	4640168	A LEGACY OF SERVICE

TRADEMARK APPLICATIONS

None.